Lin28 induces resistance to anti‐androgens via promotion of AR splice variant generation
Abstract
Prostate cancer (PCa) is androgen‐dependent initially and progresses to a castration‐resistant state after androgen deprivation therapy. Treatment options for castration‐resistant PCa include the potent second‐generation anti‐androgen enzalutamide or CYP17A1 inhibitor abiraterone. Recent clinical observations point to the development of resistance to these therapies which may be mediated by constitutively active alternative splice variants of the androgen receptor (AR).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 30, 2015
- Source ID
- 10.1002/pros.23134
Entities
People
- Allen C Gao
- Christopher P Evans
- Nagalakshmi Nadiminty
- Ramakumar Tummala
- Wei Lou
Organizations
- National Institutes of Health
- United States Department of Defense
- United States Department of Veterans Affairs
- University of California, Davis